 "Sun Pharma slips 8% as Sebi starts probe; may reopen insider trading case")
Shares of Sun Pharmaceutical Industries ended 8% lower at Rs 455 on the BSE on reports that the market regulator, the Securities and Exchange Board of India (Sebi), has initiated an inquiry into the affairs of pharma major on the basis of a whistle-blower complaint.
The stock of drug firm dipped 10% to Rs 442 in early morning trade. The trading volumes on the counter jumped four-fold with a combined 66.3 million equity shares changed hands on the BSE and NSE today.
“The market regulator was in receipt of a 150-page letter in which the whistle-blower accused the company of committing corporate governance and tax-related lapses, besides other securities market-related violations,” the Business Standard reported quoting regulatory sources.
Sebi, according to sources, also plans to reopen an insider trading case against the company and its promoters that was settled through the consent mechanism, added report. CLICK HERE TO READ FULL REPORT
Sun Pharma, its Managing Director Dilip Shanghvi, and nine others had settled the insider trading probe, paying Rs 1.8 million against the settlement charges in 2017. On response to clarification on news report" Governance cloud over Sun”, the company said the said article refers to a note circulated by one of the securities firm.
The points raised in this note pertain to historic events, some of which are dated as far back as 10-15 years. Certain points raised in the said note are incomplete and have been presented in a negative manner. The supporting information to the points raised in the note has been sourced from public domain and hence this information/data is already available in public domain. Further, there is no material impact of the said news article on the Company.
Meanwhile, the company will hold an investor call today evening at 1830 hours, where senior management will update investors. CLICK HERE FOR CALL DETAILS
The stock of drug firm dipped 10% to Rs 442 in early morning trade. The trading volumes on the counter jumped four-fold with a combined 66.3 million equity shares changed hands on the BSE and NSE today.
“The market regulator was in receipt of a 150-page letter in which the whistle-blower accused the company of committing corporate governance and tax-related lapses, besides other securities market-related violations,” the Business Standard reported quoting regulatory sources.
Sebi, according to sources, also plans to reopen an insider trading case against the company and its promoters that was settled through the consent mechanism, added report. CLICK HERE TO READ FULL REPORT
Sun Pharma, its Managing Director Dilip Shanghvi, and nine others had settled the insider trading probe, paying Rs 1.8 million against the settlement charges in 2017. On response to clarification on news report" Governance cloud over Sun”, the company said the said article refers to a note circulated by one of the securities firm.
The points raised in this note pertain to historic events, some of which are dated as far back as 10-15 years. Certain points raised in the said note are incomplete and have been presented in a negative manner. The supporting information to the points raised in the note has been sourced from public domain and hence this information/data is already available in public domain. Further, there is no material impact of the said news article on the Company.
Meanwhile, the company will hold an investor call today evening at 1830 hours, where senior management will update investors. CLICK HERE FOR CALL DETAILS
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%